STAT+

D.C. Diagnosis Sarah Owermohle

STAT Plus: The health care issues we’re watching in tonight’s VP debate

Business Tim Logan — The Boston Globe

STAT Plus: CVS to cut 2,900 jobs and is reportedly mulling a breakup

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about CVS exploring a breakup, obesity drug coverage, and more

Pharmalot Ed Silverman

STAT Plus: U.S. lawmaker urges FDA to clarify drug patent listings in a key government registry

Health tech Mohana Ravindranath

STAT Plus: Writing health AI rules: Why Micky Tripathi faces one of the toughest jobs in Washington

First Opinion Cheri Banks

STAT Plus: Five things FDA ad comm members want

Health Care Inc. Newsletter Bob Herman

STAT Plus: How much more are health care’s bosses making than their employees?

Pharma Andrew Joseph

STAT Plus: Roche seeks to project confidence on its obesity drugs — and sees room to make its mark

Pharmalot Ed Silverman

STAT Plus: J&J backs down on plan to switch payments to some 340B hospitals

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about CVS under investor pressure, a final warning to J&J and more

Exclusive Allison DeAngelis

STAT Plus: DCVC Bio founders look for more quick returns, less overhyped AI, with new $400 million fund

Biotech Jason Mast

STAT Plus: Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb

Exclusive Bob Herman, J. Emory Parker, Lizzy Lawrence, Tara Bannow, and Mohana Ravindranath

STAT Plus: Health care CEOs dialed back their pay in 2023. They still made $3.5 billion

Health tech Katie Palmer

STAT Plus: Q&A: Why medical AI and value-based care may be made for each other

Business Mark Arsenault — Boston Globe and Jessica Bartlett — Boston Globe

STAT Plus: Steward Health Care CEO Ralph de la Torre will resign

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Biotech Jonathan Wosen

STAT Plus: Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a new schizophrenia drug, a U.N. pledge on AMR and more

Health tech Brittany Trang

STAT Plus: Q&A: MedStar Health’s Raj Ratwani on health AI and the battle raging over regulation

Biotech Jonathan Wosen

STAT Plus: Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines

Pharma Adam Feuerstein

STAT Plus: FDA approves schizophrenia drug that could alter how disorder is treated

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: Medicare will continue its cautious approach to paying for Alzheimer’s drugs

Pharma Matthew Herper, Eric Boodman, Andrew Joseph, Lizzy Lawrence, Adam Feuerstein, and Jason Mast

STAT Plus: What the withdrawal of its sickle cell drug means for Pfizer, patients, and the FDA

Politics John Wilkerson and Rachel Cohrs Zhang

STAT Plus: Hassan indicates she’s open to tweaks on site-neutral payment reforms

Politics Bob Herman

STAT Plus: Biden administration axes proposal to mandate more drug price transparency in Medicaid

Politics Lizzy Lawrence

STAT Plus: FDA introduces plan to assess safety of common chemicals added to food

Health tech Casey Ross

STAT Plus: Epic Systems has been challenged in court before, but it’s different this time

Politics Isabella Cueto

STAT Plus: Head of national stockpile addresses Congress’ criticisms of outbreak response

Hospitals Tara Bannow

STAT Plus: Two reports, two dramatically different views of nonprofit hospitals’ tax breaks